Reassessing the significance of intimal arteritis in kidney transplant biopsy specimens

Journal of the American Society of Nephrology

Volumn 26, Issue 12, 2015, Pages 3190-3198

  Salazar, Israel D R ^a,b,c   López, Maribel Merino ^a   Chang, Jessica ^a   Halloran, Philip F ^a,d  

^a UNIVERSITY OF ALBERTA   (Canada)

^b Project Pacer International Boston   (Bolivia)

^c Caja National Health Hospital   (Bolivia)

^d UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; STEROID; THYMOCYTE ANTIBODY; ANTIBODY; HLA ANTIGEN;

ANTIBODY MEDIATED REJECTION; ARTERITIS; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; GRAFT FAILURE; GRAFT REJECTION; GRAFT SURVIVAL; HISTOLOGY; HUMAN; HUMAN TISSUE; INTIMAL ARTERITIS; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY GRAFT; MULTICENTER STUDY; POLYOMAVIRUS; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; T CELL MEDIATED REJECTION; TREATMENT RESPONSE; BIOPSY; IMMUNOLOGY; INTIMA; KIDNEY; KIDNEY TRANSPLANTATION; PATHOLOGY; T LYMPHOCYTE; TIME FACTOR;

ANTIBODIES; ARTERITIS; BIOPSY; GRAFT REJECTION; HLA ANTIGENS; HUMANS; KIDNEY; KIDNEY TRANSPLANTATION; PROGNOSIS; T-LYMPHOCYTES; TIME FACTORS; TUNICA INTIMA;

EID: 84958235775     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2014111064     Document Type: Article

References (41)

1. JeannetM, Pinn VW, FlaxMH,Winn HJ, Russell PS: Humoral antibodies in renal allotransplantation in man. N Engl J Med 282: 111-117, 1970
2. Solez K, Colvin RB, Racusen LC, Haas M, Sis B, Mengel M, Halloran PF, Baldwin W, Banfi G, Collins AB, Cosio F, David DS, Drachenberg C, Einecke G, Fogo AB, Gibson IW, Glotz D, Iskandar SS, Kraus E, Lerut E, Mannon RB, Mihatsch M, Nankivell BJ, Nickeleit V, Papadimitriou JC, Randhawa P, Regele H, Renaudin K, Roberts I, Seron D, Smith RN, Valente M: Banff 07 classification of renal allograft pathology: Updates and future directions. Am J Transplant 8: 753-760, 2008
3. Halloran PF: Immunosuppressive drugs for kidney transplantation. N Engl J Med 351: 2715-2729, 2004
4. Coelho T, TredgerM, Dhawan A: Current status of immunosuppressive agents for solid organ transplantation in children. Pediatr Transplant 16: 106-122, 2012
5. Sellarés J, de Freitas DG, Mengel M, Sis B, Hidalgo LG, Matas AJ, Kaplan B, Halloran PF: Inflammation lesions in kidney transplant biopsies: Association with survival is due to the underlying diseases.AmJ Transplant 11: 489-499, 2011
6. Sollinger HW, Belzer FO, Deierhoi MH, Diethelm AG, Gonwa TA, Kauffman RS, Klintmalm GB, McDiarmid SV, Roberts J, Rosenthal JT, Tomlanovich SJ: RS-61443 (mycophenolate mofetil). A multicenter study for refractory kidney transplant rejection. Ann Surg 216: 513-518, discussion 518-519, 1992
7. Sollinger HW; U.S. Renal Transplant Mycophenolate Mofetil Study Group: Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 60: 225-232, 1995
8. Magil A, Rubin J, Ladewig L, JohnsonM, Goldstein MB, Bear RA: Renal biopsy in acute allograft rejection. Significance of moderate vascular lesions in long-term graft survival. Nephron 26: 180-183, 1980
9. Matas AJ, Sibley R, Mauer M, Sutherland DE, Simmons RL, Najarian JS: The value of needle renal allograft biopsy. I. A retrospective study of biopsies performed during putative rejection episodes. Ann Surg 197: 226-237, 1983
10. Kooijmans-Coutinho MF, Hermans J, Schrama E, Ringers J, Daha MR, Bruijn JA, van der Woude FJ: Interstitial rejection, vascular rejection, and diffuse thrombosis of renal allografts. Predisposing factors, histology, immunohistochemistry, and relation to outcome. Transplantation 61: 1338-1344, 1996
11. Shimizu T, Ishida H, Shirakawa H,Omoto K, Tsunoyama K, Tokumoto T, Tanabe K: Clinicopathological analysis of acute vascular rejection cases after renal transplantation. Clin Transplant 24[Suppl 22]: 22-26, 2010
12. HaasM, Kraus ES, Samaniego-PicotaM, Racusen LC, NiW, Eustace JA: Acute renal allograft rejection with intimal arteritis: Histologic predictors of response to therapy and graft survival. Kidney Int 61: 1516-1526, 2002
13. van Saase JL, van der Woude FJ, Thorogood J, Hollander AA, van Es LA, Weening JJ, van Bockel JH, Bruijn JA: The relation between acute vascular and interstitial renal allograft rejection and subsequent chronic rejection. Transplantation 59: 1280-1285, 1995
14. Schroeder TJ, Weiss MA, Smith RD, Stephens GW, First MR: The efficacy of OKT3 in vascular rejection. Transplantation 51: 312-315, 1991
15. Haas M, Sis B, Racusen LC, Solez K, Glotz D, Colvin RB, Castro MC, David DS, David-Neto E, Bagnasco SM, Cendales LC, Cornell LD, Demetris AJ, Drachenberg CB, Farver CF, Farris AB 3rd, Gibson IW, Kraus E, LiapisH, Loupy A,Nickeleit V, Randhawa P, Rodriguez ER, Rush D, Smith RN, Tan CD, Wallace WD, Mengel M; Banff meeting report writing committee: Banff 2013 meeting report: Inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant 14: 272-283, 2014
16. Sis B, Jhangri GS, Bunnag S, Allanach K, Kaplan B, Halloran PF: Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. Am J Transplant 9: 2312-2323, 2009
17. Halloran PF, Chang J, Famulski K, Hidalgo LG, Salazar ID,Merino Lopez M, Matas A, Picton M, de Freitas D, Bromberg J, Serón D, Sellarés J, Einecke G, Reeve J: Disappearance of T cell-mediated rejection despite continued antibody-mediated rejection in late kidney transplant recipients [published online ahead of print November 6, 2014]. J Am Soc Nephrol doi:10.1681/ASN.2014060588
18. Halloran PF, Schlaut J, Solez K, Srinivasa NS: The significance of the anti-class I response. II. Clinical and pathologic features of renal transplants with anti-class I-like antibody. Transplantation 53: 550-555, 1992
19. Trpkov K, Campbell P, Pazderka F, Cockfield S, Solez K, Halloran PF: Pathologic features of acute renal allograft rejection associated with donor-specific antibody, Analysis using the Banff grading schema. Transplantation 61: 1586-1592, 1996
20. Shimizu T, Tanabe T, Shirakawa H, Omoto K, Ishida H, Tanabe K: Acute vascular rejection after renal transplantation and isolated v-lesion. Clin Transplant 26[Suppl 24]: 2-8, 2012
21. Haas M: Pathologic features of antibody-mediated rejection in renal allografts: An expanding spectrum. Curr Opin Nephrol Hypertens 21: 264-271, 2012
22. Brown CC, Sebire NJ, Wittenhagen P, Shaw O, Marks SD: Clinical significance of isolated v lesions in paediatric renal transplant biopsies: Muscular arteries required to refute the diagnosis of acute rejection. Transpl Int 27: 170-175, 2014
23. Sis B, Einecke G, Chang J, Hidalgo LG, Mengel M, Kaplan B, Halloran PF: Cluster analysis of lesions in nonselected kidney transplant biopsies: Microcirculation changes, tubulointerstitial inflammation and scarring. Am J Transplant 10: 421-430, 2010
24. Herzenberg AM, Gill JS, DjurdjevO,Magil AB: C4d deposition in acute rejection: An independent long-term prognostic factor. J Am Soc Nephrol 13: 234-241, 2002
25. Lefaucheur C, Nochy D, Hill GS, Suberbielle-Boissel C, Antoine C, Charron D, Glotz D: Determinants of poor graft outcome in patients with antibody-mediated acute rejection. Am J Transplant 7: 832-841, 2007
26. Lefaucheur C, Loupy A, Vernerey D, Duong-Van-Huyen JP, Suberbielle C, Anglicheau D, Vérine J, Beuscart T, Nochy D, Bruneval P, Charron D, Delahousse M, Empana JP, Hill GS, Glotz D, Legendre C, Jouven X: Antibody-mediated vascular rejection of kidney allografts: A population-based study. Lancet 381: 313-319, 2013
27. Nankivell BJ: Antibody-mediated vascular rejection: Relation to causation. Lancet 381: 275-277, 2013
28. Bröcker V, Hirzallah M, Gwinner W, Bockmeyer CL, Wittig J, Zell S, Agustian PA, Schwarz A, Ganzenmüller T, Zilian E, Immenschuh S, Becker JU: Histopathological and clinical findings in renal transplants with Banff type II and III acute cellular rejectionwithout tubulointerstitial infiltrates. Virchows Arch 464: 203-211, 2014
29. Reeve J, Sellarés J, Mengel M, Sis B, Skene A, Hidalgo L, de Freitas DG, Famulski KS, Halloran PF: Molecular diagnosis of T cell-mediated rejection in human kidney transplant biopsies. Am J Transplant 13: 645-655, 2013
30. Sellarés J, Reeve J, Loupy A, Mengel M, Sis B, Skene A, de Freitas DG, Kreepala C, Hidalgo LG, Famulski KS, Halloran PF:Molecular diagnosis of antibody-mediated rejection in human kidney transplants. Am J Transplant 13: 971-983, 2013
31. Halloran PF, Pereira AB, Chang J, Matas A, Picton M, De Freitas D, Bromberg J, Serón D, Sellarés J, Einecke G, Reeve J: Potential impact of microarray diagnosis of T cell-mediated rejection in kidney transplants: The INTERCOM study. Am J Transplant 13: 2352-2363, 2013
32. Halloran PF, Pereira AB, Chang J, Matas A, Picton M, De Freitas D, Bromberg J, Serón D, Sellarés J, Einecke G, Reeve J: Microarray diagnosis of antibody-mediated rejection in kidney transplant biopsies: An international prospective study (INTERCOM). Am J Transplant 13: 2865-2874, 2013
33. Mueller TF, Reeve J, Jhangri GS, Mengel M, Jacaj Z, Cairo L, Obeidat M, Todd G, Moore R, Famulski KS, Cruz J, Wishart D, Meng C, Sis B, Solez K, Kaplan B, Halloran PF: The transcriptome of the implant biopsy identifies donor kidneys at increased risk of delayed graft function. Am J Transplant 8: 78-85, 2008
34. Reeve J, Einecke G, Mengel M, Sis B, Kayser N, Kaplan B, Halloran PF: Diagnosing rejection in renal transplants: A comparison of molecularand histopathology-based approaches.AmJ Transplant 9: 1802-1810, 2009
35. Sis B, Mengel M, Haas M, Colvin RB, Halloran PF, Racusen LC, Solez K, Baldwin WM 3rd, Bracamonte ER, Broecker V, Cosio F, Demetris AJ, Drachenberg C, Einecke G, Gloor J, Glotz D, Kraus E, Legendre C, Liapis H, Mannon RB, Nankivell BJ, Nickeleit V, Papadimitriou JC, Randhawa P, Regele H, Renaudin K, Rodriguez ER, Seron D, Seshan S, Suthanthiran M, Wasowska BA, Zachary A, Zeevi A: Banff '09 meeting report: Antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant 10: 464-471, 2010
36. Einecke G, Sis B, Reeve J, Mengel M, Campbell PM, Hidalgo LG, Kaplan B,Halloran PF: Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant 9: 2520-2531, 2009
37. Loupy A, Lefaucheur C, Vernerey D, Chang J, Hidalgo LG, Beuscart T, Verine J, Aubert O, Dubleumortier S, Duong van Huyen JP, Jouven X, Glotz D, Legendre C, Halloran PF: Molecular microscope strategy to improve risk stratification in early antibody-mediated kidney allograft rejection. J Am Soc Nephrol 25: 2267-2277, 2014
38. Reeve J, Famulski K, Halloran PF, and the INTERCOM Group: Microarray gene expression for predicting histo-clinical variables in kidney transplant biopsies [Abstract]. Am J Transplant 14(S3): 890, 2014
39. Sis B, Bagnasco SM, Cornell LD, Randhawa P, HaasM, Lategan B,Magil AB, Herzenberg AM, Gibson IW, Kuperman M, Sasaki K, Kraus ES; the Banff Working Group: Isolated endarteritis and kidney transplant survival: Amulticenter collaborative study [published online ahead of print November 7, 2014]. J Am Soc Nephrol
40. Wu KY, Budde K, Schmidt D, Neumayer HH, Rudolph B: Acute cellular rejection with isolated v-lesions is not associated with more favorable outcomes than vascular rejection with more tubulointerstitial inflammations. Clin Transplant 28: 410-418, 2014
41. Sellarés J, de Freitas DG,Mengel M, Reeve J, EineckeG, Sis B, Hidalgo LG, Famulski K, Matas A, Halloran PF: Understanding the causes of kidney transplant failure: The dominant role of antibody-mediated rejection and nonadherence. Am J Transplant 12: 388-399, 2012